

KURZPROTOKOLL INSPIRE

Öffentlicher Titel	Phase III Studie zu Rigosertib bei Patienten mit MDS nach fehlgeschlagener Behandlung mit Azacitidin oder Decitabin
Wissenschaftl. Titel	A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
Kurztitel	INSPIRE
Studienart	multizentrisch, Therapiestudie, randomisiert, offen/unverblindet, zweiarmig
Studienphase	Phase III
Erkrankung	Blut: Myeloische Neoplasien/Dysplasien: Myelodysplastische Syndrome (MDS)
Einschlusskriterien	<ul style="list-style-type: none"> - MDS classified as follows: - a RAEB-1 per World Health Organization (WHO) MDS criteria (5% to 9% BM blasts) - b RAEB-2 per WHO MDS criteria (10% to 19% BM blasts) - c RAEB-t per French-American-British (FAB) classification (20% to 30% BM blasts) - Diagnosis of MDS confirmed within 8 weeks prior to the Screening Visit - At least one cytopenia (ANC < 1800/μL or platelet count < 100,000/μL or hemoglobin [Hgb] < 10 g/dL) - Progression (according to 2006 IWG criteria) at any time after initiation of AZA or DEC treatment or Failure to achieve complete or partial response or hematological improvement (HI) (according to 2006 IWG) after at least six 4-week cycles of AZA or either four 4-week or four 6-week cycles of DEC administered or Relapse after initial complete or partial response or HI (according to 2006 IWG criteria) - Duration of prior HMA therapy 9 months - Last dose of AZA or DEC within 6 months before the planned date of randomization; however, must be off these treatments for 4 weeks before randomization - Has failed to respond to, relapsed following, not eligible for, or opted not to participate in allogeneic stem cell transplantation - Off all treatments for MDS (including AZA and DEC) for 4 weeks before randomization; growth factors (G-CSF, erythropoietin and thrombopoietin) and transfusions are allowed before and during the study as clinically indicated - Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 - Willing to adhere to protocol prohibitions and restrictions - Patient (or a legally authorized representative) must sign informed consent form to indicate patient's understanding study's purpose and procedures and willingness to participate
Ausschlusskriterien	<ul style="list-style-type: none"> - Previous participation in a clinical study of IV or oral rigosertib; patients who failed screening for other rigosertib studies may be screened for participation - Eligible to receive induction chemotherapy, such as 7-10 days of cytosine arabinoside plus 2-3 days of an anthracycline, or high-dose cytarabine - Eligible to receive allogeneic stem cell transplantation - Any active malignancy within the past year, except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix or breast - Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure or unstable angina pectoris - Active infection not adequately responding to appropriate therapy - Total bilirubin 1.5 mg/dL not related to hemolysis or Gilbert's disease - Alanine transaminase (ALT)/aspartate transaminase (AST) 2.5 x upper limit of normal (ULN) - Serum creatinine 2.0 mg/dL

KURZPROTOKOLL INSPIRE

- Known HIV, hepatitis B or hepatitis C
- Uncorrected hyponatremia (defined as serum sodium value of <130 mEq/L)
- Female patients of child-bearing potential and male patients with partners of child-bearing potential who are unwilling to follow strict contraception requirements before entry and throughout the study, up to and including the 30-day non-treatment follow-up period
- Female patients of child-bearing potential who are breast-feeding or have a positive blood beta-human chorionic gonadotropin pregnancy test at Screening
- Major surgery without full recovery or within 3 weeks before planned randomization;
- Uncontrolled hypertension
- New onset seizures (within 3 months before planned randomization) or poorly controlled seizures
- Any other concurrent investigational agent or chemotherapy, radiotherapy, immunotherapy, or corticosteroids (prednisone up to 20 mg/day or its equivalent is permitted for chronic conditions)
- Treatment with cytarabine at any dose, lenalidomide, or any other therapy targeted to the treatment of MDS (other than growth factors and other supportive care measures) within 4 weeks of planned randomization
- Investigational therapy within 4 weeks of planned randomization
- Psychiatric illness or social situation that would limit the patient's ability to tolerate and/or comply with study requirements.

Alter 18 - 79 Jahre

Fallzahl 225

Prüfzentren **Universitätsmedizin Frankfurt** (Geschlossen)
Medizinische Klinik II, Hämatologie/Onkologie
Theodor-Stern-Kai 7
60590 Frankfurt am Main
Lena Schütz
Tel: 069 6301-84497
Fax: 069 6301-83655
lena.schuetz@unimedizin-ffm.de

Sponsor Onconova Therapeutics, Inc.

Förderer Onconova Therapeutics, Inc.

Registrierung in anderen Studienregistern ClinicalTrials.gov NCT02562443 (primäres Register)
EudraCT 2015-001476-22